Liquidia Technologies
About
Liquidia Technologies is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics.
- 51 - 100
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $6M
- Industries
- Biopharma,Biotechnology,Nanotechnology,Therapeutics
- Founded date
- Jan 1, 2004
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 13, 2021 | Post-IPO Equity | $21.70M | 1 |
Caligan Partners
|
— | Detail |
| Dec 26, 2019 | Post-IPO Equity | $22.40M | 2 | — | — | Detail |
| Jun 14, 2006 | Series A | $6M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Caligan Partners
|
Yes | Post-IPO Equity |
|
|
— | Post-IPO Equity |
|
|
— | Post-IPO Equity |
Siemens AG
|
— | Series A |
